Le Lézard
Classified in: Health
Subject: MAT

GVB Biopharma Begins Cannabigerol (CBG) Studies to Assess Therapeutic Potential


LAS VEGAS, Aug. 6, 2020 /PRNewswire/ -- GVB Biopharma, a pharmaceutical company specializing in hemp and cannabis-related consumer products, announced today that it has established the process and infrastructure for producing medicinal products from cannabigerol (CBG). This natural cannabinoid is a critical precursor molecule to two well-known cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD).

With this venture, GVB Biopharma creates a scientific foundation and professional network for a research and development program for CBG, allowing for the rapid development of licensable intellectual property. In addition to CBG, this well-vetted process can be used to identify and develop other target molecules of interest.

The process will be established in two phases with two parts each. In the first phase, GVB will conduct extensive literature review of research on the endocannabinoid system and the effects of CBG, using the results to create an annotated database of scientific research. Next, GVB will oversee the chemical characterization of CBG, confirming the absence of pollutants and identifying important features like potency and shelf life.

In the second phase, GVB Biopharma will create a biological characterization of CBG and assess its therapeutic potential and other meaningful uses. These efforts allow GVB to compile scientific evidence showing the value of CBG products to regulatory agencies, allowing for efficient access to the marketplace.

GVB Biopharma sets the industry standard for rigor in developing, testing and manufacturing hemp and cannabinoid products for the discerning consumer. With its state-of-the-art facilities for hemp processing in Oregon and white-label consumer product manufacturing in Nevada, GVB Biopharma sets the standard for product quality. From using rigorous research, to testing the genetic stability of seeds, to verifying the cannabinoid capacity of its plants and purity of the distilled oil, the integrity of the GVB Biopharma process is reflected in every product.

SOURCE GVB Biopharma


These press releases may also interest you

at 16:34
LUNGevity Foundation, the nation's premier lung cancer-focused nonprofit organization, in partnership with the American Cancer Society Cancer Action Network (ACS CAN), issued a report today analyzing private payer health insurance coverage of...

at 16:30
Kaiser Permanente has announced that Yazdi Bagli is the new executive vice president of Enterprise Business Services for Kaiser Permanente. In this role, he will lead, expand, and accelerate Kaiser Permanente's shared services work, overseeing the...

at 16:21
ZOSI Analytical, an elite third-party hemp analytical testing laboratory, announced today that it has completed its ISO 17025:2017 assessment with no findings and is now accredited for hemp biomass and hemp product potency testing.  Hemp growers,...

at 16:15
Fusion Pharmaceuticals Inc. , a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the appointment of Maria Stahl as chief legal officer....

at 16:14
Residents of San Antonio now have expanded access to compassionate end-of-life care through the VITAS Healthcare Inpatient Hospice Unit (IPU) at Villa Rosa Medical Plaza. Located at 5131 Medical Drive, Suite 310, this facility is expected to serve...

at 16:10
CohBar, Inc. , a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at...



News published on 6 august 2020 at 15:00 and distributed by: